These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39209325)

  • 1. Cost-effectiveness of monitoring ocular hypertension based on a risk prediction tool.
    Wu H; Gazzard G; King A; Morgan J; Wright D; Crabb DP; Takwoingi Y; Azuara-Blanco A; Watson V; Hernández R
    BMJ Open Ophthalmol; 2024 Aug; 9(1):. PubMed ID: 39209325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT.
    Gazzard G; Konstantakopoulou E; Garway-Heath D; Garg A; Vickerstaff V; Hunter R; Ambler G; Bunce C; Wormald R; Nathwani N; Barton K; Rubin G; Morris S; Buszewicz M
    Health Technol Assess; 2019 Jun; 23(31):1-102. PubMed ID: 31264958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring ocular hypertension, how much and how often? A cost-effectiveness perspective.
    Hernández R; Burr JM; Vale L; Azuara-Blanco A; Cook JA; Banister K; Tuulonen A; Ryan M;
    Br J Ophthalmol; 2016 Sep; 100(9):1263-8. PubMed ID: 26659710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance for ocular hypertension: an evidence synthesis and economic evaluation.
    Burr JM; Botello-Pinzon P; Takwoingi Y; Hernández R; Vazquez-Montes M; Elders A; Asaoka R; Banister K; van der Schoot J; Fraser C; King A; Lemij H; Sanders R; Vernon S; Tuulonen A; Kotecha A; Glasziou P; Garway-Heath D; Crabb D; Vale L; Azuara-Blanco A; Perera R; Ryan M; Deeks J; Cook J
    Health Technol Assess; 2012 Jun; 16(29):1-271, iii-iv. PubMed ID: 22687263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of treating ocular hypertension.
    Stewart WC; Stewart JA; Nasser QJ; Mychaskiw MA
    Ophthalmology; 2008 Jan; 115(1):94-8. PubMed ID: 18166406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension.
    van Gestel A; Schouten JS; Beckers HJ; Severens JL; Hendrikse F; Webers CA
    Acta Ophthalmol; 2014 Sep; 92(6):513-23. PubMed ID: 24330516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study.
    Kymes SM; Kass MA; Anderson DR; Miller JP; Gordon MO;
    Am J Ophthalmol; 2006 Jun; 141(6):997-1008. PubMed ID: 16765666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is primary trabeculectomy cost-effective for patients with advanced primary open angle glaucoma? Results from the Treatment of Advanced Glaucoma Study economic model.
    Shabaninejad H; Homer T; Kernohan A; King AJ; Burr J; Azuara-Blanco A; Vale L
    Br J Ophthalmol; 2024 Aug; 108(9):1210-1215. PubMed ID: 38336459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.
    Kaambwa B; Bryan S; Jowett S; Mant J; Bray EP; Hobbs FD; Holder R; Jones MI; Little P; Williams B; McManus RJ
    Eur J Prev Cardiol; 2014 Dec; 21(12):1517-30. PubMed ID: 23990660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension. A cost-effectiveness analysis.
    Peeters A; Schouten JS; Severens JL; Hendrikse F; Prins MH; Webers CA
    Acta Ophthalmol; 2012 Mar; 90(2):146-54. PubMed ID: 20731623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness.
    Tuulonen A; Azuara-Blanco A
    Ophthalmology; 2009 Jan; 116(1):166-7; author reply 167. PubMed ID: 19118707
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness.
    Brown GC; Brown MM
    Ophthalmology; 2008 Aug; 115(8):1433; author reply 1433-4. PubMed ID: 18675701
    [No Abstract]   [Full Text] [Related]  

  • 13. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
    Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
    J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches.
    Orme M; Collins S; Loftus J
    J Glaucoma; 2012 Sep; 21(7):433-49. PubMed ID: 21677590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness.
    Lichter PR
    Ophthalmology; 2008 Oct; 115(10):1852-3; author reply 1853. PubMed ID: 18929170
    [No Abstract]   [Full Text] [Related]  

  • 16. Direct cost and predictive factors for treatment in patients with ocular hypertension or early, moderate and advanced primary open-angle glaucoma: the CoGIS study in Germany.
    Lorenz K; Wolfram C; Breitscheidel L; Shlaen M; Verboven Y; Pfeiffer N
    Graefes Arch Clin Exp Ophthalmol; 2013 Aug; 251(8):2019-28. PubMed ID: 23624617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension.
    Kymes SM; Plotzke MR; Kass MA; Boland MV; Gordon MO
    Arch Ophthalmol; 2010 May; 128(5):613-8. PubMed ID: 20457984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary trabeculectomy versus primary glaucoma eye drops for newly diagnosed advanced glaucoma: TAGS RCT.
    King AJ; Fernie G; Hudson J; Kernohan A; Azuara-Blanco A; Burr J; Homer T; Shabaninejad H; Sparrow JM; Garway-Heath D; Barton K; Norrie J; McDonald A; Vale L; MacLennan G
    Health Technol Assess; 2021 Nov; 25(72):1-158. PubMed ID: 34854808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.
    Lubitz CC; Economopoulos KP; Sy S; Johanson C; Kunzel HE; Reincke M; Gazelle GS; Weinstein MC; Gaziano TA
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):621-30. PubMed ID: 26555126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.